Serum IL2Rα as a Diagnostic Biomarker and Its Functional Interplay With IL‐2 in Breast Cancer
The Breast Journal · 2026-01 · 2026 (1)
DOI: 10.1155/tbj/5295439 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Breast Journal, online erschienen am 22.07.2026. Verfasst von Wei Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, 100 Haining Road, Shanghai 200080, China,…. Hauptthemen laut MEDLINE: Breast Neoplasms, Biomarkers, Tumor, Interleukin-2, Interleukin-2 Receptor alpha Subunit. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Medical Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Breast cancer is a leading female malignancy, with chronic inflammation driving progression. The IL‐2/IL‐2R axis regulates immunity, but IL2RA’s role in breast cancer (expression, diagnostic/prognostic value, and interplay with IL‐2) is unclear.
Methods
A total of 252 consecutive patients (99 breast cancer and 153 benign breast disease) who received breast surgery were retrospectively analyzed. Serum cytokines were measured via electrochemiluminescence immunoassay; ROC, single‐cell sequencing, and bioinformatics databases (TIMER and Kaplan–Meier plotter) were used to assess IL2RA/IL‐2’s utility and associations.
Results
Serum IL2Rα was higher in breast cancer (336.9 vs. 275.8 U/mL, p < 0.001; no significant differences were observed for other cytokines). IL2Rα showed moderate diagnostic performance (AUC = 0.650, cut‐off = 240.5 U/mL), correlated with NLR ( p = 0.012), and showed a trend towards poor survival ( p = 0.124, HR = 0.309, 95% CI: 0.069–1.381). Single‐cell sequencing identified T cells as the primary source of IL2Rα in tumor tissues. High IL2RA expression strongly correlated with infiltration of immune cells, especially neutrophils ( r = 0.673) and dendritic cells ( r = 0.706). RNA‐seq analysis showed IL2RA was upregulated in tumor tissues, associated with poor prognosis ( p = 9.7 e − 06, HR = 1.29, 95% CI: 1.15–1.44) and aggressive features (e.g., lymph node metastasis and HER2 positivity). In contrast, IL‐2 was highly expressed in normal tissues, linked to better prognosis ( p = 0.001, HR = 0.83, 95% CI: 0.74–0.93), and had opposing clinical correlations.
Conclusions
Serum IL2Rɑ could serve as a complementary auxiliary diagnostic biomarker for breast cancer, with associations with systemic inflammation, immune cell infiltration, and aggressive disease. The functional antagonism between IL2RA and IL‐2 highlights the IL‐2/IL2RA axis as a critical regulator of breast cancer pathophysiology, supporting its potential as a therapeutic target for improving breast cancer diagnosis and treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, 100 Haining Road, Shanghai 200080, China, shsmu.edu.cn.
- Department of Nursing, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, 100 Haining Road, Shanghai 200080, China, shsmu.edu.cn.
Förderung
- Beijing Medical Foundation
- National Natural Science Foundation of China
Zitieren
APA
Wang, W., Liu, J., Wei, Y., Fang, Y., Ding, S., Liu, D., & Zhu, L. (2026). Serum IL2Rα as a Diagnostic Biomarker and Its Functional Interplay With IL‐2 in Breast Cancer. The Breast Journal, 2026(1). https://doi.org/10.1155/tbj/5295439
Vancouver
Wang W, Liu J, Wei Y, Fang Y, Ding S, Liu D, et al. Serum IL2Rα as a Diagnostic Biomarker and Its Functional Interplay With IL‐2 in Breast Cancer. The Breast Journal. 2026;2026(1). doi:10.1155/tbj/5295439
BibTeX
@article{Wang2026,
author = {Wang, Wei and Liu, Jun and Wei, Yun and Fang, Yan and Ding, Shuning and Liu, Deyue and Zhu, Li},
title = {Serum IL2Rα as a Diagnostic Biomarker and Its Functional Interplay With IL‐2 in Breast Cancer},
journal = {The Breast Journal},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/tbj/5295439}
}
EUVIMED